Literature DB >> 1355913

Purification of HlyX, a potential regulator of haemolysin synthesis, and properties of HlyX:FNR hybrids.

J Green1, A D Sharrocks, J I MacInnes, J R Guest.   

Abstract

The hlyX gene of the swine pathogen Actinobacillus pleuropneumoniae is homologous to FNR, an anaerobic transcriptional regulator of Escherichia coli. It endows a haemolytic phenotype upon E. coli, and will complement the anaerobic respiratory deficiencies of fnr mutants of E. coli. The coding region of the hlyX gene was expressed in E. coli and the HlyX protein was purified by using an assay based on its immunological cross-reactivity with anti-FNR antibodies. The HlyX protein had the predicted N-terminal sequence, and resembled the isolated FNR protein in size (Mr 29,000) and monomeric organization. It has no detectable haemolysin activity per se, and is therefore presumed to confer a haemolytic phenotype by activating a latent haemolysin gene in E. coli. Studies with gene fusions showed that HlyX, like FNR, can function as an anaerobic activator and repressor of FNR-regulated genes in vivo. Plasmids that express hybrid HlyX:FNR proteins in which the 189/190-residue N-terminal segments and the remaining 50/60-residue C-terminal segments are exchanged, retained their FNR-specific functions but failed to confer a haemolytic phenotype. This suggests that the specificity for activating the haemolytic response requires the participation of unique features in both the N- and C-terminal segments of HlyX.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355913     DOI: 10.1098/rspb.1992.0045

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  2 in total

1.  Cloning and characterization of a Prevotella melaninogenica hemolysin.

Authors:  H E Allison; J D Hillman
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

Review 2.  The FNR family of transcriptional regulators.

Authors:  S Spiro
Journal:  Antonie Van Leeuwenhoek       Date:  1994       Impact factor: 2.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.